Dapivirine vaginal ring effective and acceptable with longer use
Does Descovy have a role as PrEP in people who struggle with adherence?
Policing practices are consistently associated with HIV and risk behaviours among people who inject drugs
First trial results of new immune-modulating drugs presented in Mexico City
Could integrating HIV prevention into contraceptive services reduce infections among African women?
Starting PrEP does not lead to more STIs, youth survey in Chicago finds
Who stops taking PrEP, and why?
Islatravir plus doravirine may offer new dual therapy option
Trial vaccine could protect against HIV for more than five years
Four days on, three days off HIV treatment as effective as continuous therapy, French study finds
ADVANCE trial shows dolutegravir is highly effective in South Africa
Three forms of PrEP stigma in Kenya
PrEP implant could last well over a year
WHO endorses event-driven PrEP for gay men
South Africa saves $326 million on dolutegravir
Men accounted for two-thirds of HIV transmission in PopART prevention trial
Dolutegravir leads to weight gain in two African studies
Home tests aren’t an accurate way for people on HIV treatment to check they still have HIV
